Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T13:22:31.705Z Has data issue: false hasContentIssue false
  • English
  • Français

Pindolol augmentation of antidepressant therapy

Published online by Cambridge University Press:  03 January 2018

Robyn McAskill ,
Shameem Mir  and
David Taylor
Robyn McAskill
Affiliation:
Maudsley Hospital, London SE5 8AZ
Shameem Mir
Affiliation:
Maudsley Hospital, London SE5 8AZ
David Taylor
Affiliation:
Maudsley Hospital, London SE5 8AZ
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Antidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated as a potential accelerator and augmenter of antidepressant response.

Method

A Medline search was conducted in November 1997.

Results

Six open-label studies and six controlled studies were identified for review Conclusions Open-label studies strongly suggest that pindolol may accelerate and augment antidepressant response, but controlled studies do not wholly support these findings: only three of six studies clearly demonstrate benefit. Larger, well-designed, controlled trials are needed to determine definitively the effectiveness of pindolol in this context.

Type
Review Articles
Information
The British Journal of Psychiatry , Volume 173 , Issue 3 , September 1998 , pp. 203 - 208
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Artigas, F. (1995) Pindolol, 5-hydroxytryptamine and antidepressant augmentation. Archives of General Psychiatry, 52, 969–971.CrossRefGoogle ScholarPubMed
Artigas, F. Perez, V. & Alvarez, E. (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin re-uptake inhibitors. Archives of General Psychiatry, 51, 248–251.Google Scholar
Bakish, D. Hooper, C. L. Thornton, M. D. et al (1997) Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy. International Clinical Psychopharmacology, 12, 91–97.Google Scholar
Berman, R. M. Darnell, a. M. Miller, H. L. et al (1997) Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double blind, placebo-controlled trial. American Journal of Psychiatry, 154, 37–43.Google ScholarPubMed
Blier, P. & Bergeron, R. (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. Journal of Clinical Psychopharmacology, 15, 217–222.Google Scholar
Blier, P. Bergeron, R. & Montigny, C. (1997) Selective activation of postsynaptic 5-HTIA receptors induces rapid antidepressant response. Neuropsychopharmacology, 316, 333–338.Google Scholar
Blier, P. LeBel, M. & Hadrava, V. (1998) Sertraline versus paroxetine effects on pindolol pharmacokinetics (abstract). In New Research – Programme and Abstracts (APA Annual Meeting), pp. 261–262. Washington, DC: APA.Google Scholar
Dinan, T. G. & Scott, L. V. (1996) Does pindolol induce a rapid improvement in depressed patients resistant to serotonin reuptake inhibitors? Journal of Serotonin Research, 3, 119–121.Google Scholar
Hamilton, M. (1967) Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology, 6, 278–296.Google Scholar
Kraus, R. P. (1996) Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine. Depression, 4, 92–94.Google Scholar
Kraus, R. P. (1997) Pindolol augmentation of tranylcypromine in psychotic depression. Journal of Clinical Psychopharmacology, 17, 225–226.CrossRefGoogle ScholarPubMed
Maes, M. Vandoolaeghe, E. & Desnyder, R. (1996) Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of Affective Disorders, 41, 201–210.Google ScholarPubMed
Moreno, F. A. Gelenberg, A. J. Bachar, K. et al (1997) Pindolol augmentation of treatment-resistant depressed patients. Journal of Clinical Psychiatry, 58, 437–439.Google Scholar
Perez, V. Gilaberte, I. Faries, D. et al (1997) Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet, 349, 1594–1597.CrossRefGoogle ScholarPubMed
Taylor, D. & Lader, M. (1996) Cytochromes and psychotropic drug interactions. British Journal of Psychiatry, 168, 529–532.Google Scholar
Taylor, D. Duncan, D. McConnell, H. et al (1997) The Maudsley Prescribing Guidelines (4th edn). London: Maudsley Hospital.Google Scholar
Tome, M. B. Isaac, M. T. & Holland, C. (1997) Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology, 12, 81–89.Google Scholar
Vinar, O. Vinarova, E. & Horacek, J. (1996) Pindolol accelerates the therapeutic action of selective serotonin reuptake inhibitors (SSRI) in depression. Homeostasis. 37, 93–95.Google Scholar
Zancardi, R. Artiges, F. Franchini, L. et al (1997) How long should pindolol be associated with paroxetine to improve the antidepressant response? Journal of Clinical Psychopharmacology, 17, 446–450.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.